Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways

Biotechnology Advances

Volumn 33, Issue 6, 2015, Pages 785-797

  Morceau, Franck ^a   Chateauvieux, Sébastien ^a   Orsini, Marion ^a   Trécul, Anne ^a   Dicato, Mario ^a   Diederich, Marc ^b  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b Seoul National University   (South Korea)

Author keywords

Cancer; Differentiation therapy; Drug development; Gene expression; Leukemia; Natural compounds

Indexed keywords

CELL DEATH; CELL PROLIFERATION; CHEMICAL COMPOUNDS; COMPLEX NETWORKS; CYTOLOGY; DISEASES; DRUG PRODUCTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENES;

ACUTE MYELOID LEUKEMIA; ALL-TRANS RETINOIC ACIDS; CANCER; COMPLEX REGULATORY NETWORK; DRUG DEVELOPMENT; EPIGENETIC REGULATION; LEUKEMIA; NATURAL COMPOUNDS;

CELLS;

APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG; DRUG DEVELOPMENT; GENE EXPRESSION; GROWTH; MATURATION;

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ANIMAL; CELL DIFFERENTIATION; DRUG EFFECTS; HUMAN; LEUKEMIA; MOUSE; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CELL DIFFERENTIATION; HUMANS; LEUKEMIA; MICE; NEOPLASTIC PROCESSES; SIGNAL TRANSDUCTION;

EID: 84939260659     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.03.013     Document Type: Review

References (166)

1. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981, 78:4990-4994.
2. Ablain J., de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011, 117:5795-5802.
3. Advani A.S., Pendergast A.M. Bcr-Abl variants: biological and clinical aspects. Leuk Res 2002, 26:713-720.
4. Athanasiou M., Mavrothalassitis G., Sun-Hoffman L., Blair D.G. FLI-1 is a suppressor of erythroid differentiation in human hematopoietic cells. Leukemia 2000, 14:439-445.
5. Attar E.C., Johnson J.L., Amrein P.C., Lozanski G., Wadleigh M., DeAngelo D.J., et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75years: CALGB (Alliance) study 10502. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31:923-929.
6. Baum K.J., Ren R. Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol 2008, 1:5.
7. +-dependent apoptosis. Blood 2008, 111:2354-2363.
8. Beutler J.A., Karbon E.W., Brubaker A.N., Malik R., Curtis D.R., Enna S.J. Securinine alkaloids: a new class of GABA receptor antagonist. Brain Res 1985, 330:135-140.
9. Blaheta R.A., Cinatl J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002, 22:492-511.
10. Blobel G.A., Nakajima T., Eckner R., Montminy M., Orkin S.H. CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci U S A 1998, 95:2061-2066.
11. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005, 65:9943-9952.
12. Breitman T.R., Selonick S.E., Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980, 77:2936-2940.
13. Bresnick E.H., Lee H.Y., Fujiwara T., Johnson K.D., Keles S. GATA switches as developmental drivers. J Biol Chem 2010, 285:31087-31093.
14. Brown G., Choudhry M.A., Durham J., Drayson M.T., Michell R.H. Monocytically differentiating HL60 cells proliferate rapidly before they mature. Exp Cell Res 1999, 253:511-518.
15. Broxmeyer H.E., Douglas G.W., Hangoc G., Cooper S., Bard J., English D., et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 1989, 86:3828-3832.
16. Broxmeyer H.E., Cooper S., Hangoc G., Kim C.H. Stromal cell-derived factor-1/CXCL12 selectively counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell proliferation in vitro. Stem Cells Dev 2005, 14:199-203.
17. Buck I., Morceau F., Cristofanon S., Heintz C., Chateauvieux S., Reuter S., et al. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation. Biochem Pharmacol 2008, 76:1229-1239.
18. Buck I., Morceau F., Cristofanon S., Reuter S., Dicato M., Diederich M. The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. Int J Oncol 2009, 34:853-860.
19. Buck I., Morceau F., Grigorakaki C., Dicato M., Diederich M. Linking anemia to inflammation and cancer: the crucial role of TNFalpha. Biochem Pharmacol 2009, 77:1572-1579.
20. Burger P.E., Dowdle E.B., Lukey P.T., Wilson E.L. Basic fibroblast growth factor antagonizes transforming growth factor beta-mediated erythroid differentiation in K562 cells. Blood 1994, 83:1808-1812.
21. Cairoli R., Beghini A., Grillo G., Nadali G., Elice F., Ripamonti C.B., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107:3463-3468.
22. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003, 121:775-777.
23. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I clinical results. Blood 1990, 76:1704-1709.
24. Chan H.L., Yip H.Y., Mak N.K., Leung K.N. Modulatory effects and action mechanisms of tryptanthrin on murine myeloid leukemia cells. Cell Mol Immunol 2009, 6:335-342.
25. Chateauvieux S., Morceau F., Dicato M., Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010.
26. Chateauvieux S., Eifes S., Morceau F., Grigorakaki C., Schnekenburger M., Henry E., et al. Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem Pharmacol 2011, 81:498-509.
27. Chaturvedi P., Sharma S., Reddy E.P. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol Cell Biol 1997, 17:3295-3304.
28. Chen Y., Sprung R., Tang Y., Ball H., Sangras B., Kim S.C., et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteomics 2007, 6:812-819.
29. Chen Y., Lu N., Ling Y., Gao Y., Wang L., Sun Y., et al. Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction. Toxicology 2009, 259:10-17.
30. Chen Y., Hui H., Yang H., Zhao K., Qin Y., Gu C., et al. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood 2013, 121:3682-3691.
31. Darley R.L., Pearn L., Omidvar N., Sweeney M., Fisher J., Phillips S., et al. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 2002, 100:4185-4192.
32. Deangelo D.J., Neuberg D., Amrein P.C., Berchuck J., Wadleigh M., Sirulnik L.A., et al. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res 2014, 38:430-434.
33. Detmer K., Walker A.N., Jenkins T.M., Steele T.A., Dannawi H. Erythroid differentiation in vitro is blocked by cyclopamine, an inhibitor of hedgehog signaling. Blood Cells Mol Dis 2000, 26:360-372.
34. Deubzer H., Busche B., Ronndahl G., Eikel D., Michaelis M., Cinatl J., et al. Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells. Leuk Res 2006, 30:1167-1175.
35. Di Bacco A., Keeshan K., McKenna S.L., Cotter T.G. Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis. Oncologist 2000, 5:405-415.
36. Dore L.C., Crispino J.D. Transcription factor networks in erythroid cell and megakaryocyte development. Blood 2011, 118:231-239.
37. Dore L.C., Chlon T.M., Brown C.D., White K.P., Crispino J.D. Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis. Blood 2012, 119:3724-3733.
38. Dupont C., Couillerot E., Gillet R., Caron C., Zeches-Hanrot M., Riou J.F., et al. The benzophenanthridine alkaloid fagaronine induces erythroleukemic cell differentiation by gene activation. Planta Med 2005, 71:489-494.
39. Elagib K.E., Racke F.K., Mogass M., Khetawat R., Delehanty L.L., Goldfarb A.N. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 2003, 101:4333-4341.
40. Ema H., Morita Y., Suda T. Heterogeneity and hierarchy of hematopoietic stem cells. Exp Hematol 2014, 42:74-82.
41. Fenaux P., Wang Z.Z., Degos L. Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 2007, 313:101-128.
42. Ferreira R., Ohneda K., Yamamoto M., Philipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 2005, 25:1215-1227.
43. Freemantle S.J., Spinella M.J., Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003, 22:7305-7315.
44. Friedman A.D., Keefer J.R., Kummalue T., Liu H., Wang Q.F., Cleaves R. Regulation of granulocyte and monocyte differentiation by CCAAT/enhancer binding protein alpha. Blood Cells Mol Dis 2003, 31:338-341.
45. Garcia P., Berlanga O., Vegiopoulos A., Vyas P., Frampton J. c-Myb and GATA-1 alternate dominant roles during megakaryocyte differentiation. Genes Cells 2011, 9:1572-1581.
46. Gelmetti V., Zhang J., Fanelli M., Minucci S., Pelicci P.G., Lazar M.A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998, 18:7185-7191.
47. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
48. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
49. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
50. Gregory T., Yu C., Ma A., Orkin S.H., Blobel G.A., Weiss M.J. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999, 94:87-96.
51. Grigorakaki C., Morceau F., Chateauvieux S., Dicato M., Diederich M. Tumor necrosis factor alpha-mediated inhibition of erythropoiesis involves GATA-1/GATA-2 balance impairment and PU.1 over-expression. Biochem Pharmacol 2011, 82:156-166.
52. Gupta K., Chakrabarti A., Rana S., Ramdeo R., Roth B.L., Agarwal M.L., et al. Securinine, a myeloid differentiation agent with therapeutic potential for AML. PLoS One 2011, 6. [e21203].
53. Gutierrez P., Delgado M.D., Richard C., Moreau-Gachelin F., Leon J. Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells. Biochem Biophys Res Commun 1997, 240:862-868.
54. Hantschel O., Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004, 5:33-44.
55. Hara E.S., Ono M., Kubota S., Sonoyama W., Oida Y., Hattori T., et al. Novel chondrogenic and chondroprotective effects of the natural compound harmine. Biochimie 2013, 95:374-381.
56. Harigae H., Takahashi S., Suwabe N., Ohtsu H., Gu L., Yang Z., et al. Differential roles of GATA-1 and GATA-2 in growth and differentiation of mast cells. Genes Cells 1998, 3:39-50.
57. Hart A., Melet F., Grossfeld P., Chien K., Jones C., Tunnacliffe A., et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000, 13:167-177.
58. Hatano R., Takano F., Fushiya S., Michimata M., Tanaka T., Kazama I., et al. Water-soluble extracts from Angelica acutiloba Kitagawa enhance hematopoiesis by activating immature erythroid cells in mice with 5-fluorouracil-induced anemia. Exp Hematol 2004, 32:918-924.
59. Heisterkamp N., Groffen J. Molecular insights into the Philadelphia translocation. Hematol Pathol 1991, 5:1-10.
60. Hirasawa R., Shimizu R., Takahashi S., Osawa M., Takayanagi S., Kato Y., et al. Essential and instructive roles of GATA factors in eosinophil development. J Exp Med 2002, 195:1379-1386.
61. Honma Y., Okabe-Kado J., Hozumi M., Uehara Y., Mizuno S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res 1989, 49:331-334.
62. Honma Y., Okabe-Kado J., Kasukabe T., Hozumi M., Umezawa K. Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells. Jpn J Cancer Res 1990, 81:1132-1136.
63. Horita M., Andreu E.J., Benito A., Arbona C., Sanz C., Benet I., et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000, 191:977-984.
64. Huang Y., Zhao Q., Zhou C.X., Gu Z.M., Li D., Xu H.Z., et al. Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells. Oncogene 2006, 25:6618-6627.
65. Huang K.F., Zhang G.D., Huang Y.Q., Diao Y. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. Int Immunopharmacol 2012, 12:334-341.
66. Ikemoto S., Sugimura K., Yoshida N., Yasumoto R., Wada S., Yamamoto K., et al. Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 2000, 55:951-955.
67. Ikonomi P., Noguchi C.T., Miller W., Kassahun H., Hardison R., Schechter A.N. Levels of GATA-1/GATA-2 transcription factors modulate expression of embryonic and fetal hemoglobins. Gene 2000, 261:277-287.
68. Ikonomi P., Rivera C.E., Riordan M., Washington G., Schechter A.N., Noguchi C.T. Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation. Exp Hematol 2000, 28:1423-1431.
69. Iland H.J., Bradstock K., Supple S.G., Catalano A., Collins M., Hertzberg M., et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012, 120:1570-1580. [quiz 752].
70. Ilaria R.L., Van Etten R.A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271:31704-31710.
71. Iriyama N., Yuan B., Yoshino Y., Hatta Y., Horikoshi A., Aizawa S., et al. Enhancement of differentiation induction and upregulation of CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with combination of ATRA and valproic acid. Int J Oncol 2014, 44:865-873.
72. Jeannesson P., Lahlil R., Chenais B., Devy L., Gillet R., Aries A., et al. Anthracyclines as tumor cell differentiating agents: effects on the regulation of erythroid gene expression. Leuk Lymphoma 1997, 26:575-587.
73. Jelkmann W. Regulation of erythropoietin production. J Physiol 2011, 589:1251-1258.
74. Johnson D.E., Redner R.L. An ATRActive future for differentiation therapy in AML. Blood Rev 2015.
75. Kihara T., Ichikawa S., Yonezawa T., Lee J.W., Akihisa T., Woo J.T., et al. Acerogenin A, a natural compound isolated from Acer nikoense Maxim, stimulates osteoblast differentiation through bone morphogenetic protein action. Biochem Biophys Res Commun 2011, 406:211-217.
76. Kim J.M., Lee S.U., Kim Y.S., Min Y.K., Kim S.H. Baicalein stimulates osteoblast differentiation via coordinating activation of MAP kinases and transcription factors. J Cell Biochem 2008, 104:1906-1917.
77. Koschmieder S., Halmos B., Levantini E., Tenen D.G. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J. Clin. Oncol. 2009, 27:619-628.
78. Kurzrock R., Gutterman J.U., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988, 319:990-998.
79. Lecanu L., Hashim A.I., McCourty A., Papadopoulos V. A steroid isolated from the water mold Achlya heterosexualis induces neurogenesis in vitro and in vivo. Steroids 2012, 77:224-232.
80. Leszczyniecka M., Roberts T., Dent P., Grant S., Fisher P.B. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001, 90:105-156.
81. Libregts S.F., Gutierrez L., de Bruin A.M., Wensveen F.M., Papadopoulos P., van Ijcken W., et al. Chronic IFN-gamma production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood 2011, 118:2578-2588.
82. Lim B.O. Effects of wogonin, wogonoside, and 3,5,7,2',6'-pentahydroxyflavone on chemical mediator production in peritoneal exduate cells and immunoglobulin E of rat mesenteric lymph node lymphocytes. J Ethnopharmacol 2003, 84:23-29.
83. Liu B., Ohishi K., Yamamura K., Suzuki K., Monma F., Ino K., et al. A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis. Exp Hematol 2010, 38:685-695.
84. Lubick K., Radke M., Jutila M. Securinine, a GABAA receptor antagonist, enhances macrophage clearance of phase II C. burnetii: comparison with TLR agonists. J Leukoc Biol 2007, 82:1062-1069.
85. Mandanas R.A., Leibowitz D.S., Gharehbaghi K., Tauchi T., Burgess G.S., Miyazawa K., et al. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993, 82:1838-1847.
86. Marchwicka A., Cebrat M., Sampath P., Sniezewski L., Marcinkowska E. Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin D analogs. Front. Oncol. 2014, 4:125.
87. Marcinkowska E., Garay E., Gocek E., Chrobak A., Wang X., Studzinski G.P. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. Exp Cell Res 2006, 312:2054-2065.
88. Mathieu J., Ruohola-Baker H. Regulation of stem cell populations by microRNAs. Adv Exp Med Biol 2013, 786:329-351.
89. Matsumoto A., Mizukami H., Mizuno S., Umegaki K., Nishikawa J., Shudo K., et al. beta-cryptoxanthin, a novel natural RAR ligand, induces ATP-binding cassette transporters in macrophages. Biochem Pharmacol 2007, 74:256-264.
90. Miccio A., Wang Y., Hong W., Gregory G.D., Wang H., Yu X., et al. NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J 2010, 29:442-456.
91. Moise A.R., Noy N., Palczewski K., Blaner W.S. Delivery of retinoid-based therapies to target tissues. Biochemistry 2007, 46:4449-4458.
92. Molkentin J.D. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 2000, 275:38949-38952.
93. Morceau F., Aries A., Lahlil R., Devy L., Jardillier J.C., Jeannesson P., et al. Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells. Biochem Pharmacol 1996, 51:839-845.
94. Morceau F., Chenais B., Gillet R., Jardillier J.C., Jeannesson P., Trentesaux C. Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Cell Growth Differ 1996, 7:1023-1029.
95. Morceau F., Dupont C., Palissot V., Borde-Chiche P., Trentesaux C., Dicato M., et al. GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the gamma-globin mRNA. Leukemia 2000, 14:1589-1597.
96. Morceau F., Schnekenburger M., Blasius R., Buck I., Dicato M., Diederich M. Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. Cancer Lett 2006, 240:203-212.
97. Morceau F., Buck I., Dicato M., Diederich M. Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation. Biofactors 2008, 34:313-329.
98. Morceau F., Dicato M., Diederich M. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm 2009, 2009:405016.
99. Moreau-Gachelin F., Wendling F., Molina T., Denis N., Titeux M., Grimber G., et al. Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 1996, 16:2453-2463.
100. Musialik E., Bujko M., Kober P., Grygorowicz M.A., Libura M., Przestrzelska M., et al. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients. Leuk Res 2014, 38:850-856.
101. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003, 112:859-871.
102. Nagy L., Kao H.Y., Love J.D., Li C., Banayo E., Gooch J.T., et al. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev 1999, 13:3209-3216.
103. Nakamaki T., Okabe-Kado J., Yamamoto-Yamaguchi Y., Hino K., Tomoyasu S., Honma Y., et al. Role of MmTRA1b/phospholipid scramblase1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes. Exp Hematol 2002, 30:421-429.
104. Neubauer A., Dodge R.K., George S.L., Davey F.R., Silver R.T., Schiffer C.A., et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994, 83:1603-1611.
105. Newmark H.L., Lupton J.R., Young C.W. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett 1994, 78:1-5.
106. Okamoto R., Akagi T., Koeffler P. Vitamin D compounds and myelodysplastic syndrome. Leuk Lymphoma 2008, 49:12-13.
107. Osti F., Corradini F.G., Hanau S., Matteuzzi M., Gambari R. Human leukemia K562 cells: induction to erythroid differentiation by guanine, guanosine and guanine nucleotides. Haematologica 1997, 82:395-401.
108. Pae H.O., Oh H., Choi B.M., Oh G.S., Paik S.G., Jeong S., et al. Differentiation-inducing effects of verticinone, an isosteroidal alkaloid isolated from the bulbus of Fritillaria ussuriensis, on human promyelocytic leukemia HL-60 cells. Biol Pharm Bull 2002, 25:1409-1411.
109. Pane F., Frigeri F., Sindona M., Luciano L., Ferrara F., Cimino R., et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996, 88:2410-2414.
110. Pang L., Xue H.H., Szalai G., Wang X., Wang Y., Watson D.K., et al. Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins. Blood 2006, 108:2198-2206.
111. Paquette R.L., Koeffler H.P. Differentiation therapy. Hematol Oncol Clin North Am 1992, 6:687-706.
112. Petrie K., Zelent A., Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009, 16:84-91.
113. Pevny L., Lin C.S., D'Agati V., Simon M.C., Orkin S.H., Costantini F. Development of hematopoietic cells lacking transcription factor GATA-1. Development 1995, 121:163-172.
114. Powers M.V., Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13(Suppl. 1):S125-S135.
115. Raffoux E., Cras A., Recher C., Boelle P.Y., de Labarthe A., Turlure P., et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010, 1:34-42.
116. Rana S., Gupta K., Gomez J., Matsuyama S., Chakrabarti A., Agarwal M.L., et al. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. FASEB J. 2010, 24:2126-2134.
117. Reddy V.A., Iwama A., Iotzova G., Schulz M., Elsasser A., Vangala R.K., et al. Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood 2002, 100:483-490.
118. Reiss M., Gamba-Vitalo C., Sartorelli A.C. Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep 1986, 70:201-218.
119. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998, 12:968-981.
120. Romeo P.H., Prandini M.H., Joulin V., Mignotte V., Prenant M., Vainchenker W., et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature 1990, 344:447-449.
121. Rosenbauer F., Wagner K., Kutok J.L., Iwasaki H., Le Beau M.M., Okuno Y., et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004, 36:624-630.
122. Rulina A.V., Spirin P.V., Prassolov V.S. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition. Biochem. Biokhimiia 2010, 75:1650-1666.
123. Sahu S.K., Gummadi S.N., Manoj N., Aradhyam G.K. Phospholipid scramblases: an overview. Arch Biochem Biophys 2007, 462:103-114.
124. Sato S., Sakashita A., Ishiyama T., Nakamaki T., Hino K., Tomoyasu S., et al. Possible differentiation treatment with aclacinomycin A in acute myelomonocytic leukemia refractory to conventional chemotherapy. Anticancer Res 1992, 12:371-376.
125. Sawyers C.L., Denny C.T., Witte O.N. Leukemia and the disruption of normal hematopoiesis. Cell 1991, 64:337-350.
126. Sawyers C.L., McLaughlin J., Witte O.N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995, 181:307-313.
127. Sayo T., Sugiyama Y., Inoue S. Lutein, a nonprovitamin A, activates the retinoic acid receptor to induce HAS3-dependent hyaluronan synthesis in keratinocytes. Biosci Biotechnol Biochem 2013, 77:1282-1286.
128. Schnur R.C., Corman M.L., Gallaschun R.J., Cooper B.A., Dee M.F., Doty J.L., et al. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995, 38:3813-3820.
129. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D., et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998, 3:100-108.
130. Shia W.J., Okumura A.J., Yan M., Sarkeshik A., Lo M.C., Matsuura S., et al. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood 2012, 119:4953-4962.
131. Sillaber C., Gesbert F., Frank D.A., Sattler M., Griffin J.D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000, 95:2118-2125.
132. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997, 16:6151-6161.
133. Song H.D., Sun X.J., Deng M., Zhang G.W., Zhou Y., Wu X.Y., et al. Hematopoietic gene expression profile in zebrafish kidney marrow. Proc Natl Acad Sci U S A 2004, 101:16240-16245.
134. Supko J.G., Hickman R.L., Grever M.R., Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995, 36:305-315.
135. Szalai G., LaRue A.C., Watson D.K. Molecular mechanisms of megakaryopoiesis. Cell. Mol. Life Sci.: CMLS 2006, 63:2460-2476.
136. Tabe Y., Konopleva M., Munsell M.F., Marini F.C., Zompetta C., McQueen T., et al. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004, 103:1815-1822.
137. Tai M.C., Tsang S.Y., Chang L.Y., Xue H. Therapeutic potential of wogonin: a naturally occurring flavonoid. CNS Drug Rev 2005, 11:141-150.
138. Takahashi T., Kawakami K., Mishima S., Akimoto M., Takenaga K., Suzumiya J., et al. Cyclopamine induces eosinophilic differentiation and upregulates CD44 expression in myeloid leukemia cells. Leuk Res 2011, 35:638-645.
139. Tanabe H., Yasui T., Kotani H., Nagatsu A., Makishima M., Amagaya S., et al. Retinoic acid receptor agonist activity of naturally occurring diterpenes. Bioorg Med Chem 2014, 22:3204-3212.
140. Tanaka H., Abe E., Miyaura C., Shiina Y., Suda T. 1 alpha,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. Biochem Biophys Res Commun 1983, 117:86-92.
141. Tang J.L., Hou H.A., Chen C.Y., Liu C.Y., Chou W.C., Tseng M.H., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114:5352-5361.
142. Tokunaga M., Ezoe S., Tanaka H., Satoh Y., Fukushima K., Matsui K., et al. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1. J Biol Chem 2010, 285:31774-31782.
143. Trecul A., Morceau F., Dicato M., Diederich M. Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network. Genes Nutr 2012, 7:111-125.
144. Trecul A., Morceau F., Gaigneaux A., Schnekenburger M., Dicato M., Diederich M. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochem Pharmacol 2014, 92:299-311.
145. Trentesaux C., Nyoung M.N., Aries A., Morceau F., Ronchi A., Ottolenghi S., et al. Increased expression of GATA-1 and NFE-2 erythroid-specific transcription factors during aclacinomycin-mediated differentiation of human erythroleukemic cells. Leukemia 1993, 7:452-457.
146. Tsang A.P., Visvader J.E., Turner C.A., Fujiwara Y., Yu C., Weiss M.J., et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 1997, 90:109-119.
147. Tsolmon S., Nakazaki E., Han J., Isoda H. Apigetrin induces erythroid differentiation of human leukemia cells K562: proteomics approach. Mol Nutr Food Res 2011, 55(Suppl. 1):S93-S102.
148. Vegiopoulos A., Garcia P., Emambokus N., Frampton J. Coordination of erythropoiesis by the transcription factor c-Myb. Blood 2006, 107:4703-4710.
149. Vicente C., Conchillo A., Garcia-Sanchez M.A., Odero M.D. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol 2012, 82:1-17.
150. Wadman I.A., Osada H., Grutz G.G., Agulnick A.D., Westphal H., Forster A., et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 1997, 16:3145-3157.
151. Wang W., Guo Q., You Q., Zhang K., Yang Y., Yu J., et al. Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721. Anticancer Drugs 2006, 17:797-805.
152. Wang W., Guo Q.L., You Q.D., Zhang K., Yang Y., Yu J., et al. The anticancer activities of wogonin in murine sarcoma S180 both in vitro and in vivo. Biol Pharm Bull 2006, 29:1132-1137.
153. Wang S., Wang Z., Lin S., Zheng W., Wang R., Jin S., et al. Revealing a natural marine product as a novel agonist for retinoic acid receptors with a unique binding mode and inhibitory effects on cancer cells. Biochem J 2012, 446:79-87.
154. Welch J.S., Niu H., Uy G.L., Westervelt P., Abboud C.N., Vij R., et al. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am J Hematol 2014, 89:E103-E108.
155. Wen Q., Goldenson B., Crispino J.D. Normal and malignant megakaryopoiesis. Expert Rev Mol Med 2011, 13. [e32].
156. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
157. Wickrema A., Crispino J.D. Erythroid and megakaryocytic transformation. Oncogene 2007, 26:6803-6815.
158. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., van Putten W.L., Valk P.J., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
159. Wu X., Chen H., Sun J., Peng Y., Liang Y., Wang G., et al. Development and validation of a liquid chromatography-mass spectrometry method for the determination of verticinone in rat plasma and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2067-2071.
160. Yang H., Hui H., Wang Q., Li H., Zhao K., Zhou Y., et al. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Oncotarget 2014, 5:8188-8201.
161. Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T., et al. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 1996, 56:2945-2948.
162. Zhang P., Zhang X., Iwama A., Yu C., Smith K.A., Mueller B.U., et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 2000, 96:2641-2648.
163. Zhang K., Guo Q.L., You Q.D., Yang Y., Zhang H.W., Yang L., et al. Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression. Cancer Sci 2008, 99:689-695.
164. Zhang S.J., Ma L.Y., Huang Q.H., Li G., Gu B.W., Gao X.D., et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A 2008, 105:2076-2081.
165. Zheng X., Oancea C., Henschler R., Ruthardt M. Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells. Int J Oncol 2009, 34:1521-1531.
166. Zhou Q., Zhao J., Wiedmer T., Sims P.J. Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1. Blood 2002, 99:4030-4038.